Search

Displaying results 1451 - 1460 of 10000 in total
  1. Drug

    Pegfilgrastim

    go.drugbank.com/drugs/DB00019
    ApprovedInvestigational

    [A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological … [A187631] Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop longer-acting

    Categories: Compounds used in a research, industrial, or household settingProducts: Pelgraz 6 mg solution for injection in a pre-filled syringe, NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML
  2. Drug

    Hexaminolevulinate

    go.drugbank.com/drugs/DB06261
    ApprovedInvestigational

    of a prior cystoscopy. … Karl Storz Photodynamic Diagnostic D-Light C (PDD) System for cystoscopic detection of non-muscle invasive papillary cancer of the bladder for patients suspected or known to have lesion(s) on the basis

  3. Drug

    Anisindione

    go.drugbank.com/drugs/DB01125
    Approved

    Anisindione is a synthetic anticoagulant and an indanedione derivative. … well as the anticoagulant proteins C and S, in the liver.

  4. Drug

    Halothane

    go.drugbank.com/drugs/DB01159
    ApprovedVet approvedWithdrawn

    A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly.

  5. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

    Mixtures: Urin D/S, Uretron D/S
  6. Drug

    Avapritinib

    go.drugbank.com/drugs/DB15233
    ApprovedInvestigational

    [A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal

  7. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative … However, due to its modified Fc region, margetuximab binds with higher affinity to both CD16A variants and exhibits weaker binding to the inhibitory CD32B Fc receptor, resulting in more efficient antibody-dependent

  8. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.

  9. Drug

    Benralizumab

    go.drugbank.com/drugs/DB12023
    ApprovedInvestigational

    [A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. … It is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells, macrophages and neutrophils.

  10. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9092] Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.[L9122,L9125] … [A187202,A187205] Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria, having received approval in the EU in December 2014[L9119] and subsequent

    Categories: Compounds used in a research, industrial, or household setting